Alnylam Pharma (ALNY) Tops Q2 EPS by 24c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Raymond James Upgrades Alnylam Pharmaceuticals (ALNY) to Strong Buy
August 3, 2026 7:20 AM EDTRaymond James analyst Martin Auster upgraded Alnylam Pharmaceuticals (NASDAQ: ALNY) from Outperform to Strong Buy with a price target of $420.00.
The analyst comments "ALNY shares are -35% since early July on a series of events that have called LT growth potential for... More
